Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade with chemotherapy could overcome these barriers. Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC.

Materials and methods

This was a single-institution study with a 3 + 3 dose-escalation design. The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included determining the toxicity profile, objective response rate (ORR), median progression-free survival (PFS), and overall survival (OS).

Results

Twe

SUBMITTER: Kamath SD 

PROVIDER: S-EPMC7216436 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature